Display options
Cite
Cocco E, Marrosu MG. Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis. Ther Clin Risk Manag. 2015;11:759-66doi: 10.2147/TCRM.S69123.
Cocco, E., & Marrosu, M. G. (2015). Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis. Therapeutics and clinical risk management, 11759-66. https://doi.org/10.2147/TCRM.S69123
Cocco, Eleonora, and Marrosu, Maria Giovanna. "Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis." Therapeutics and clinical risk management vol. 11 (2015): 759-66. doi: https://doi.org/10.2147/TCRM.S69123
Cocco E, Marrosu MG. Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis. Ther Clin Risk Manag. 2015 May 08;11:759-66. doi: 10.2147/TCRM.S69123. eCollection 2015. PMID: 26056458; PMCID: PMC4431469.
Copy Download .nbib Format: NLM
Share it on

Ther Clin Risk Manag. 2015 May 08;11:759-66. doi: 10.2147/TCRM.S69123. eCollection 2015.

Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis.

Therapeutics and clinical risk management

Eleonora Cocco, Maria Giovanna Marrosu

Affiliations

  1. Multiple Sclerosis Center, Department of Public Health, Clinical and Molecular Medicine, University of Cagliari, Cagliari, Italy.

PMID: 26056458 PMCID: PMC4431469 DOI: 10.2147/TCRM.S69123

Abstract

Several treatments are currently available for relapsing-remitting multiple sclerosis. Among them, interferon (IFN) beta remains a valid treatment approach because of its good benefit/risk profile. Due to the need for frequent administration (weekly, at a minimum), the use of IFN beta is limited by uncomfortable side effects that could reduce adherence to and persistence with the treatment. The use of subcutaneous polyethylene glycol (PEG)ylated interferon beta-1a (PEG-IFN) has been proposed to offer a better combination of pharmacokinetic and pharmacodynamic profiles and therapy-related side effects. A 125 μg dose of PEG-IFN given every 2 or 4 weeks was tested in two Phase I studies and shown to be as safe and efficient as IFN beta-1a but with a longer half-life. A Phase III trial (ADVANCE) comparing 125 μg of PEG-IFN given every 2 or 4 weeks with placebo in 1,512 patients with relapsing-remitting multiple sclerosis showed significant reductions in both the annualized relapse rate (ARR) and the occurrence of new or newly enlarged T2 brain lesions in both experimental groups versus placebo after the first year. Moreover, 38% fewer patients showed progression of disability (P=0.04) in the PEG-IFN groups. During the second year, the ARR was further reduced in the PEG-IFN 2-week treatment group (0.230 at 1 year versus 0.178 at 2 years) and was maintained in the 4-week treatment group. Patients who received immediate PEG-IFN treatment showed improved clinical efficacy (ARR, risk of relapse, 12-week disability progression) and magnetic resonance imaging parameters (new T2 and newly enlarging lesions, gadolinium-positive lesions) compared with those with delayed treatment. The effects were more evident with the 2-week dose for all endpoints considered. Furthermore, PEG-IFN was well tolerated, and no new safety concerns arose. In conclusion, PEG-IFN has good efficacy and a good safety profile. The available data support the use of PEG-IFN as a suitable therapeutic option in patients with relapsing-remitting multiple sclerosis.

Keywords: PEGylated interferon beta; disease-modifying drug; magnetic resonance imaging; multiple sclerosis; relapses; safety

References

  1. Mult Scler. 2014 Aug;20(9):1265-8 - PubMed
  2. Neurology. 2004 Nov 23;63(10):1788-95 - PubMed
  3. Neurology. 2001 Jun 12;56(11):1505-13 - PubMed
  4. Cytokine Growth Factor Rev. 2015 Apr;26(2):221-8 - PubMed
  5. BMC Neurol. 2014 Dec 31;14:240 - PubMed
  6. J Control Release. 2007 Jun 4;119(2):236-44 - PubMed
  7. Biologics. 2013;7:131-8 - PubMed
  8. Lancet. 1998 Nov 7;352(9139):1498-504 - PubMed
  9. Ann Clin Transl Neurol. 2014 Aug;1(8):622-31 - PubMed
  10. Toxicol Sci. 1998 Apr;42(2):152-7 - PubMed
  11. N Engl J Med. 2000 Sep 28;343(13):898-904 - PubMed
  12. Transl Res. 2007 Jun;149(6):333-42 - PubMed
  13. Neurology. 2002 Nov 26;59(10):1496-506 - PubMed
  14. Ann Neurol. 1998 Jan;43(1):79-87 - PubMed
  15. Neurology. 1993 Apr;43(4):655-61 - PubMed
  16. Neurology. 2006 Oct 10;67(7):1242-9 - PubMed
  17. Lancet. 2001 May 19;357(9268):1576-82 - PubMed
  18. J Clin Pharmacol. 2012 Jun;52(6):798-808 - PubMed
  19. J Pharm Sci. 2010 Jun;99(6):2557-75 - PubMed
  20. Neurology. 1997 Aug;49(2):358-63 - PubMed
  21. Neurology. 1993 Apr;43(4):662-7 - PubMed
  22. Neurology. 2002 Sep 10;59(5):679-87 - PubMed
  23. Mult Scler. 2012 Jul;18(7):932-46 - PubMed
  24. Eur Neurol. 2014;72(3-4):132-41 - PubMed
  25. Neurology. 2001 Jun 12;56(11):1496-504 - PubMed
  26. J Neurol Sci. 2009 Dec;287 Suppl 1:S46-9 - PubMed
  27. Mult Scler. 2015 Jul;21(8):1025-35 - PubMed
  28. Expert Opin Drug Deliv. 2014 Nov;11(11):1713-20 - PubMed
  29. Pharm Res. 2005 Jan;22(1):58-61 - PubMed
  30. J Clin Pharmacol. 2015 Feb;55(2):179-88 - PubMed
  31. Expert Opin Drug Deliv. 2009 Jan;6(1):1-16 - PubMed
  32. Lancet. 1998 Nov 7;352(9139):1491-7 - PubMed
  33. N Engl J Med. 2014 Mar 27;370(13):1270-1 - PubMed
  34. Zhonghua Yi Xue Za Zhi. 2008 Jan 8;88(2):96-100 - PubMed
  35. Mult Scler. 2010 Dec;16(12):1414-21 - PubMed
  36. Lancet. 2002 Apr 27;359(9316):1453-60 - PubMed
  37. Bioconjug Chem. 2006 May-Jun;17(3):618-30 - PubMed
  38. Lancet Neurol. 2014 Jul;13(7):657-65 - PubMed

Publication Types